TISIDB

Summary
Symbol	PPP1R1C
Name	protein phosphatase 1, regulatory (inhibitor) subunit 1C
Aliases	Inhibitor-1-like; IPP5; PP1 inhibitor protein 5; inhibitor-5 of protein phosphatase 1; Protein phosphatase 1 ......
Chromosomal Location	2q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm
Domain	PF05395 Protein phosphatase inhibitor 1/DARPP-32
Function	Inhibitor of protein-phosphatase 1. Promotes cell growth and cell cycle progress at the G1/S transition. May increase cell susceptibility to TNF-induced apoptosis.

> Gene Ontology [ TOP ]
Biological Process	GO:0000082 G1/S transition of mitotic cell cycle GO:0001558 regulation of cell growth GO:0001933 negative regulation of protein phosphorylation GO:0006469 negative regulation of protein kinase activity GO:0007346 regulation of mitotic cell cycle GO:0016049 cell growth GO:0030307 positive regulation of cell growth GO:0033673 negative regulation of kinase activity GO:0042326 negative regulation of phosphorylation GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044843 cell cycle G1/S phase transition GO:0045787 positive regulation of cell cycle GO:0045927 positive regulation of growth GO:0045931 positive regulation of mitotic cell cycle GO:0051348 negative regulation of transferase activity GO:0090068 positive regulation of cell cycle process GO:1900087 positive regulation of G1/S transition of mitotic cell cycle GO:1901987 regulation of cell cycle phase transition GO:1901989 positive regulation of cell cycle phase transition GO:1901990 regulation of mitotic cell cycle phase transition GO:1901992 positive regulation of mitotic cell cycle phase transition GO:1902806 regulation of cell cycle G1/S phase transition GO:1902808 positive regulation of cell cycle G1/S phase transition GO:2000045 regulation of G1/S transition of mitotic cell cycle
Molecular Function	GO:0004857 enzyme inhibitor activity GO:0004864 protein phosphatase inhibitor activity GO:0004865 protein serine/threonine phosphatase inhibitor activity GO:0019208 phosphatase regulator activity GO:0019212 phosphatase inhibitor activity GO:0019888 protein phosphatase regulator activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	PPP1R1C
Name	protein phosphatase 1, regulatory (inhibitor) subunit 1C
Aliases	Inhibitor-1-like; IPP5; PP1 inhibitor protein 5; inhibitor-5 of protein phosphatase 1; Protein phosphatase 1 ......
Chromosomal Location	2q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PPP1R1C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PPP1R1C
Name	protein phosphatase 1, regulatory (inhibitor) subunit 1C
Aliases	Inhibitor-1-like; IPP5; PP1 inhibitor protein 5; inhibitor-5 of protein phosphatase 1; Protein phosphatase 1 ......
Chromosomal Location	2q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PPP1R1C in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PPP1R1C
Name	protein phosphatase 1, regulatory (inhibitor) subunit 1C
Aliases	Inhibitor-1-like; IPP5; PP1 inhibitor protein 5; inhibitor-5 of protein phosphatase 1; Protein phosphatase 1 ......
Chromosomal Location	2q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PPP1R1C in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.026	0.942
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.666	0.262
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.439	0.386
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.146	0.767
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.06	0.948
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.411	0.681
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.573	0.475
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-2.435	0.053
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.399	0.287
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-2.347	0.0301
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-2.347	0.0931
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.268	0.263

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PPP1R1C in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	PPP1R1C
Name	protein phosphatase 1, regulatory (inhibitor) subunit 1C
Aliases	Inhibitor-1-like; IPP5; PP1 inhibitor protein 5; inhibitor-5 of protein phosphatase 1; Protein phosphatase 1 ......
Chromosomal Location	2q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPP1R1C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PPP1R1C
Name	protein phosphatase 1, regulatory (inhibitor) subunit 1C
Aliases	Inhibitor-1-like; IPP5; PP1 inhibitor protein 5; inhibitor-5 of protein phosphatase 1; Protein phosphatase 1 ......
Chromosomal Location	2q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPP1R1C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPP1R1C. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PPP1R1C
Name	protein phosphatase 1, regulatory (inhibitor) subunit 1C
Aliases	Inhibitor-1-like; IPP5; PP1 inhibitor protein 5; inhibitor-5 of protein phosphatase 1; Protein phosphatase 1 ......
Chromosomal Location	2q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPP1R1C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PPP1R1C
Name	protein phosphatase 1, regulatory (inhibitor) subunit 1C
Aliases	Inhibitor-1-like; IPP5; PP1 inhibitor protein 5; inhibitor-5 of protein phosphatase 1; Protein phosphatase 1 ......
Chromosomal Location	2q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PPP1R1C expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PPP1R1C
Name	protein phosphatase 1, regulatory (inhibitor) subunit 1C
Aliases	Inhibitor-1-like; IPP5; PP1 inhibitor protein 5; inhibitor-5 of protein phosphatase 1; Protein phosphatase 1 ......
Chromosomal Location	2q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PPP1R1C and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PPP1R1C
Name	protein phosphatase 1, regulatory (inhibitor) subunit 1C
Aliases	Inhibitor-1-like; IPP5; PP1 inhibitor protein 5; inhibitor-5 of protein phosphatase 1; Protein phosphatase 1 ......
Chromosomal Location	2q31.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PPP1R1C collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PPP1R1C